These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36222016)

  • 41. Direct health care costs associated with COVID-19 in the United States.
    DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
    J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
    [No Abstract]   [Full Text] [Related]  

  • 42. Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States.
    Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Romanov V; Cong Z
    Clin Ther; 2018 Oct; 40(10):1711-1719.e1. PubMed ID: 30196935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic burden of sickle cell disease in Brazil.
    Silva-Pinto AC; Costa FF; Gualandro SFM; Fonseca PBB; Grindler CM; Souza Filho HCR; Bueno CT; Cançado RD
    PLoS One; 2022; 17(6):e0269703. PubMed ID: 35709301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
    Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
    PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
    Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
    J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
    Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
    J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases.
    Setyawan J; Billmyer E; Mu F; Yarur A; Zichlin ML; Yang H; Downes N; Azimi N; Strand V
    Adv Ther; 2022 Jan; 39(1):767-778. PubMed ID: 34905149
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
    Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
    Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone.
    Ben-Joseph R; Bell JA; Chitnis A; Kansal A; Holly P; Paramore C; Wild H
    J Med Econ; 2016; 19(2):169-80. PubMed ID: 26451633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
    Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
    Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.
    De Franceschi L; Castiglioni C; Condorelli C; Valsecchi D; Premoli E; Fiocchi C; Perrone V; Esposti LD; Forni GL; On Behalf Of The GREATalyS Study Group
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost.
    Peterson EE; Salemi JL; Dongarwar D; Salihu HM
    Eur J Pediatr; 2020 Nov; 179(11):1701-1710. PubMed ID: 32394268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data.
    Marvel J; Vlahiotis A; Sainski-Nguyen A; Willson T; Kimball A
    BMJ Open; 2019 Sep; 9(9):e030579. PubMed ID: 31575575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
    Blinder MA; Duh MS; Sasane M; Trahey A; Paley C; Vekeman F
    J Emerg Med; 2015 Oct; 49(4):513-522.e1. PubMed ID: 25910824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States.
    Naidu SS; Sutton MB; Gao W; Fine JT; Xie J; Desai NR; Owens AT
    J Med Econ; 2023; 26(1):682-690. PubMed ID: 37170479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of risk and economic burden of surgical site infection (SSI) posthysterectomy using a U.S. longitudinal database.
    Edmiston CE; Bond-Smith G; Spencer M; Chitnis AS; Holy CE; Po-Han Chen B; Leaper DJ
    Surgery; 2022 May; 171(5):1320-1330. PubMed ID: 34973811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States.
    Zhdanava M; Voelker J; Pilon D; Joshi K; Morrison L; Sheehan JJ; Vermette-Laforme M; Lefebvre P; Citrome L
    J Affect Disord; 2022 Aug; 311():303-310. PubMed ID: 35597466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
    Shukla N; Barner JC; Lawson KA; Rascati KL
    J Opioid Manag; 2021; 17(4):301-310. PubMed ID: 34533824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy.
    Pilon D; Karkare S; Zhdanava M; Sheehan JJ; Côté-Sergent A; Shah A; Lopena OJ; Lefebvre P; Joshi K; Citrome L
    J Med Econ; 2021; 24(1):1299-1308. PubMed ID: 34763603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.